«ÉÏһƪ/Previous Article|±¾ÆÚĿ¼/Table of Contents|ÏÂһƪ/Next Article»

¡¶ÐÄÔàÔÓÖ¾¡·[ISSN:1009-7236/CN:61-1268/R]

ÆÚÊý:

2006ÄêµÚ6ÆÚ

Ò³Âë:

653-655

À¸Ä¿:

ÁÙ´²Ñо¿

³ö°æÈÕÆÚ:

2006-12-25

ÎÄÕÂÐÅÏ¢/Info

Title:

Efficacy and safety of intravenous plus oral metoprolol in patients with acute myocardial infarction

×÷Õß:

ÑîÓ¹; º«ÑÅÁá²; Ù¡Ãú²; ÍõЧÔö²; ÍõÊØÁ¦²; ¼Ö¹úÁ¼¹

1.µÚËľüÒ½´óѧµÚÒ»¸½ÊôÒ½ÔºÐÄÔàÄÚ¿Æ£¬ÉÂÎ÷ Î÷°² 710032£»2.ÉòÑô¾üÇø×ÜÒ½ÔºÐÄѪ¹ÜÄÚ¿Æ£¬ÁÉÄþ ÉòÑô 110016

Author(s):

YANG Yong¹;  HAN Ya-ling²;  TONG Ming²;  WANG Xiao-zeng²;  WANG Shou-li²;  JIA Guo-liang¹

1.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi¡äan£¬ Shaanxi 710032, China; 2.Department of Cardiology, PLA General Hospital, Shenyang Military Area Command, Shenyang, Laoning 110016, China

¹Ø¼ü´Ê:

¦Â-ÊÜÌå×èÖͼÁ; Ðļ¡¹£Èû; ¼±ÐÔ; ÃÀÍÐÂå¶û

Keywords:

¦Â-blocker;  myocardial infarction; acute

·ÖÀàºÅ:

R541.4

DOI:

-

ÎÄÏ×±êʶÂë:

A

ÕªÒª:

Ä¿µÄ ̽ÌÖ¾²×¢¼°¿Ú·þÃÀÍÐÂå¶û¶Ô¼±ÐÔÐļ¡¹£ËÀ£¨AMI£©»¼Õß°²È«ÐÔ¼°ÁÙ´²ÁÆЧ¡£·½·¨ 365Àý·¢²¡ÔÚ24 hÄÚµÄAMI»¼ÕßËæ»ú·Ö³ÉÃÀÍÐÂå¶ûÖÎÁÆ×飨n=182Àý£©ºÍ¶ÔÕÕ×飨n=183Àý£©£¬ÔÚ³£¹æÖÎÁƵĻù´¡ÉÏ£¬ÖÎÁÆ×é¸øÓè¾²×¢¼°¿Ú·þÃÀÍÐÂå¶û£¬¶ÔÕÕ×é¸øÓ谲ο¼Á£¬¹Û²ìÁ½×黼ÕßÁÙ´²ÌØÕ÷£¬×¡ÔºÆÚ¼äÖÎÁÆÇ°ºóƽ¾ùѪѹ¡¢ÐÄÂʼ°Ö÷ÒªÐÄÔ಻Á¼Ê¼þ·¢ÉúÇé¿ö¡£½á¹û ÃÀÍÐÂå¶û×黼ÕßÎüÑ̺ÍÒû¾Æ»¼ÕߵıÈÀýÏÔÖø¸ßÓÚ¶ÔÕÕ×飨P<0.05)£¬ÆäËûÒ»°ãÁÙ´²ÌØÕ÷Ïàͬ£»ÃÀÍÐÂå¶û×黼ÕßÓÃÒ©Ç°ºóѪѹ¼°ÐÄÂÊϽµ·ù¶ÈÓë¶ÔÕÕ×éÏà±È¾ù´æÔÚÏÔÖøÐÔ²îÒ죨P<0.05)£»ÃÀÍÐÂå¶û×黼Õß·¢Éú¹£ËÀºóÐĽÊÍ´ºÍÊÒÐÔÐÄÂÉʧ³£µÄ±ÈÂÊÏÔÖøÉÙÓÚ¶ÔÕÕ×飨P<0.05£©£¬·¢ÉúÔÙ¹£¡¢ÄÔ¹£¡¢ÐÄÔ´ÐÔÐݿ˺ÍסԺÆÚ¼äËÀÍöµÄ±ÈÂÊ£¬Óë¶ÔÕÕ×éÏà±ÈÎÞͳ¼Æѧ²îÒì¡£½áÂÛ ÔçÆÚ¾²×¢¼°¿Ú·þÃÀÍÐÂå¶û£¬¿ÉÃ÷ÏÔ½µµÍAMI»¼ÕßÊÒÐÔÐÄÂÉʧ³£ºÍ¹£ËÀºóÐĽÊÍ´·¢ÉúÂÊ£¬µ«²¢²»½µµÍסԺÆÚ¼ä×ܵIJ¡ËÀÂÊ¡£

Abstract:

AIM To evaluate the safety and efficacy of intravenous plus oral metoprolol in acute myocardial infarction patients. METHODS Patients within 24h of suspected acute MI onset were randomly allocated metoprolol (n=182) or matching placebo (n=183). Clinical features, average blood pressure and heart rate before and after treatment and major adverse cardiac events (mace) were compared and analyzed in the two groups. RESULTS There were no significant differences in clinical features between metoprolol group and placebo group, except for those with a history of smoking and drinking in metoprolol group£¨P<0.05£©. But there were statistical differences in the changes of average blood pressure and heart rate after treatment between the two groups£¨P<0.05£© and statistical differences were also found in ventricular arrhythmias and postinfarction angina between the two groups. No significant differences were found in reinfarction, cerebral infarction, cardiac shock and mortality during the hospitalization. CONCLUSION Early intravenous plus oral metoprolol significantly reduces ventricular arrhythmias and postinfarction angina pectoris, but it will not reduce the total inª²hospital mortality in patients with acute myocardial infarction.

²Î¿¼ÎÄÏ×/References

£Û1£Ý Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. treatment following myocardial infarction£ÛJ£Ý. JAMA,1988,260(14):2088-2093.

£Û2£Ý ISISª²I (First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISISª²I£ÛJ£Ý. Lancet, 1986, 2(8498):57-66.

£Û3£Ý the MIAMI Trial Research Group. Metoprolol in acute myocardiol infarction. Patient population £ÛJ£Ý. Am J Cardiol, 1985,56(14):10G-14G.

£Û4£Ý Lindholm LH, Carlberg B, Samuelson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaª²analysis£ÛJ£Ý. Lancet,2005,366(9496):1545-1553.

£Û5£Ý ÖлªÒ½Ñ§»áÐÄѪ¹Ü²¡Ñ§·Ö»á,ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾±à¼­Î¯Ô±»á. ÖйúÑ­»·ÔÓÖ¾±à¼­Î¯Ô±»á. ¼±ÐÔÐļ¡¹£ËÀÕï¶ÏºÍÖÎÁÆÖ¸ÄÏ£ÛJ£Ý.ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2001,29(12):710-725.

£Û6£Ý Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions £ÛJ£Ý. Cardiovasc Res, 1997,33(2):243-257.

£Û7£Ý Cruickshank JM. Betaª²blockers continue to surprise us£ÛJ£Ý.Eur Heart J,2000,21(5):354-364.

£Û8£Ý Yeager MP, Fillinger MP, Hettleman BD, et al. Perioperative betaª²blockade and late cardiac outcomes: a complementary hypothesis£ÛJ£Ý. J Cardiothorac Vasc Anesth, 2005,19(2):237-241.

£Û9£Ý Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTOª²I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries £ÛJ£Ý. J Am Coll Cardiol, 1998,32(3):634-640.

£Û10£ÝLanfear DE, Jones PG, Marsh S, et al.Beta2ª²Adrenergic receptor genotype and survival among patients receiving blocker therapy after an acute coronary syndrome£ÛJ£Ý. JAMA, 2005,294(12):1526 1533.

£Û11£ÝChen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placeboª²controlled trial£ÛJ£Ý.Lancet,2005,366(9497):1622-1632.

£Û12£ÝThe MIAMI Trial Research Group. metoprolol in acute myocardial infarction (MIAMI). A randomised placebo controlled international trial£ÛJ£Ý. Eur Heart J,1985,6(3):199-226.

£Û13£ÝLubsen J, Tisjssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unite:findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT) £ÛJ£Ý. Am J Cardiol, 1987,60(2):18A-25A.

±¸×¢/Memo

±¸×¢/Memo:

ÊÕ¸åÈÕÆÚ£º2006-04-28.×÷Õß¼ò½é£ºÑîÓ£¬²©Ê¿Éú£¬Tel:(024)23051599 Email: yangyongfmmu@sina.com

³£Óù¦ÄÜ

¸üÐÂÈÕÆÚ/Last Update: